These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18976405)

  • 21. Non-melanoma skin cancers: immunohistochemical markers in diagnosis.
    Ratnam KV
    Singapore Med J; 1989 Feb; 30(1):15-6. PubMed ID: 2480648
    [No Abstract]   [Full Text] [Related]  

  • 22. Spitz nevus with an uncertain malignant potential.
    Stănescu L; Popescu CF; Georgescu I; Georgescu CV; Anghelina L; Petrescu I; Călin G
    Rom J Morphol Embryol; 2009; 50(2):275-82. PubMed ID: 19434323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo anti-melanoma activities of the Melan-A/MART-1(101-115) T CD4+ cell peptide.
    Balasse E; Gatouillat G; Patigny D; Andry MC; Madoulet C
    Vaccine; 2009 Oct; 27(44):6107-9. PubMed ID: 19686694
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
    Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
    Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous melanoma in the elderly.
    Testori A; Soteldo J; Sances D; Mazzarol G; Trifirò G; Zonta M; Rastrelli M; Schenone F; Verrecchia F
    Melanoma Res; 2009 Jun; 19(3):125-34. PubMed ID: 19381113
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current concepts in cutaneous melanoma: malignant melanoma.
    Doben AR; MacGillivray DC
    Surg Clin North Am; 2009 Jun; 89(3):713-25. PubMed ID: 19465207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The most common challenges in melanoma diagnosis and how to avoid them.
    Marghoob AA; Changchien L; DeFazio J; Dessio WC; Malvehy J; Zalaudek I; Halpern AC; Scope A
    Australas J Dermatol; 2009 Feb; 50(1):1-13; quiz 14-5. PubMed ID: 19178485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [New directions in melanoma therapy].
    Tüting T
    J Dtsch Dermatol Ges; 2008 Oct; 6(10):815-6. PubMed ID: 18992024
    [No Abstract]   [Full Text] [Related]  

  • 29. [Which diagnostic tools in melanoma and why?].
    Grob JJ
    Ann Dermatol Venereol; 2008 Dec; 135(12):812-4. PubMed ID: 19084689
    [No Abstract]   [Full Text] [Related]  

  • 30. [Reactivity of five different antibodies with benign and malignant melanocytic lesions].
    Plótár V; Szentirmay Z; Orosz Z
    Magy Onkol; 2008 Dec; 52(4):363-73. PubMed ID: 19068464
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
    Jandus C; Bioley G; Dojcinovic D; Derré L; Baitsch L; Wieckowski S; Rufer N; Kwok WW; Tiercy JM; Luescher IF; Speiser DE; Romero P
    Cancer Res; 2009 Oct; 69(20):8085-93. PubMed ID: 19808957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Melanoma-associated markers expression in blood: MUC-18 is associated with advanced stages in melanoma patients.
    Rapanotti MC; Bianchi L; Ricozzi I; Campione E; Pierantozzi A; Orlandi A; Chimenti S; Federici G; Bernardini S
    Br J Dermatol; 2009 Feb; 160(2):338-44. PubMed ID: 19067715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DMBT1 expression distinguishes anorectal from cutaneous melanoma.
    Helmke BM; Renner M; Poustka A; Schirmacher P; Mollenhauer J; Kern MA
    Histopathology; 2009 Jan; 54(2):233-40. PubMed ID: 19207948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-melanocytic mimics of melanoma, part II: intradermal mimics.
    Tong LC; Kamil ZS; Al Habeeb A; Ghazarian D
    J Clin Pathol; 2009 Apr; 62(4):290-307. PubMed ID: 19017682
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic manual of malignant melanoma].
    Moroi Y
    Fukuoka Igaku Zasshi; 2009 Feb; 100(2):51-8. PubMed ID: 19455975
    [No Abstract]   [Full Text] [Related]  

  • 36. Follow-up of melanoma patients: the need for evidence-based protocols.
    Francken AB; Hoekstra HJ
    Ann Surg Oncol; 2009 Apr; 16(4):804-5. PubMed ID: 19189190
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytokeratin expression in malignant melanoma: potential application of in-situ hybridization analysis of mRNA.
    Chen N; Gong J; Chen X; Xu M; Huang Y; Wang L; Geng N; Zhou Q
    Melanoma Res; 2009 Apr; 19(2):87-93. PubMed ID: 19190520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnostic pitfalls in mammary pathology. Case 8. Breast metastases of a malignant melanoma].
    Dauplat MM; Penault-Llorca F
    Ann Pathol; 2009 Jun; 29(3):228-32. PubMed ID: 19619831
    [No Abstract]   [Full Text] [Related]  

  • 39. Complete loss of epithelial antigens in a recurrent tumour from squamous cell carcinoma of the scalp.
    Tseng JT; Chen WY; Wang KH; Tsai TH
    J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1098-9. PubMed ID: 19175483
    [No Abstract]   [Full Text] [Related]  

  • 40. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.